BIG PACLITAXEL DEBATE

• Paclitxel eluting devices should be forgotten as they do more harm than benefit patient K. Katsanos (GR)
• Paclitaxel eluting devices has indications and should be used as they reduce mortality and amputations Ch.-A. Behrendt (DE)
• According to SWEDPAD, paclitaxel eluting devices do not increase mortality and thus may be used in selective patients J. Nordanstig (SE)

ANGIOSOME CONCEPT

• Angiosome concept is nonsense. It is enough to achieve an open arteria line to the foot and wound healing is able to reach if the line stays open F. Vermassen ( BE)
• Angiosome cotargeted revascularization leads to quicker wound healing and should be the first goal in revascularization M. Venermo (FI)

SEX DISPARITIES IN THE MANAGEMENT OF PAOD Ch.-A. Behrendt (DE)

• a.ICVR-Report C Behrendt group shows remarkable variation
• b.disadvantage of women regarding optimal pharmacological treatment
• c.CLTI women fare better after OPEN Surgical bypass regarding survival, amputation and cv events, 3rd paper)
• INVITED COMMENTARY F. Dick (CH)

HOW EXTREME YOU CAN GO IN ULTRADISTAL REVASCULARIZATION

• Open surgery: bypass to the foot T. Auvinen (FI)
• Endovascular miracles in foot L. Patrone (UK)
• Antiplatelet/Anticoagulation use in RCTs of PAOD patients undergoing endo-therapy (SR shows that guidance is urgently needed) Ch. Twine ( UK)
• Antiplatelet together with long term rivaroxabahn and one month Clopidogrel is recommended S. Debus (DE)